{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-013653","form_type":"8-K","ticker":"RNXT","cik":"0001574094","company_name":"RenovoRx, Inc.","filed_at":"2026-03-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.502397+00:00","generated_at":"2026-05-15T08:23:09.344007+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"RenovoRx reports 2025 revenue of $1.1M from RenovoCath; net loss $11.2M; cash $13M after $10M financing","bullets":["FY2025 revenue $1.1M vs $43K in 2024; first full year of RenovoCath commercialization; cost of revenue $327K, gross profit $796K.","Net loss $11.2M ($0.32 diluted EPS) vs $8.8M ($0.40) in 2024; R&D spend $6.3M, SG&A $7.0M.","Phase III TIGeR-PaC trial: 104 patients randomized (target 114), 72 deaths; enrollment completion expected mid-2026, final data 2027.","12 U.S. cancer centers actively using RenovoCath as of Feb 2026; 33 centers in pipeline; $400M peak U.S. TAM for device.","Appointed Mark Voll as CFO in Feb 2026; closed $10M private placement (net $9.2M) on Mar 20, 2026; cash $13M on hand."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-013653","json":"https://secwatch.observer/filing/0001493152-26-013653.json","markdown":"https://secwatch.observer/filing/0001493152-26-013653.md","text":"https://secwatch.observer/filing/0001493152-26-013653.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1574094/000149315226013653/0001493152-26-013653-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1574094/000149315226013653/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:23:09.344007+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4b26648ea9bb6b9a8696540006998f7f24484a39","claim":"RenovoRx, Inc. reported fiscal year ended December 31, 2025 results: revenue $1.1 million.","evidence_excerpt":"For the year ending December 31, 2025, the Company generated $1.1 million in revenue from RenovoCath sales, driven by both new cancer centers adopting the device and repeat orders from existing customers.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1574094/000149315226013653/0001493152-26-013653-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal year ended December 31, 2025"},{"label":"Revenue","value":"$1.1 million"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}